Stimulan
April 30, 2024Supermag B6 tab
April 30, 2024Stugeron
34.50 EGP
25 mg 30 tablet
Tradename:
Stugeron
Compound:
Each tablet contains:
Cinnarizine 25 mg
Auxiliary components:
Lactose monohydrate, starch, sucrose, talc, povidone.
Properties:
Cinnarizine is a selective blocker of “slow” calcium channels, reduces the entry of calcium ions into cells and reduces their concentration in the plasma membrane depot, reduces the tone of the smooth muscles of arterioles, and enhances the vasodilating effect of carbon dioxide. Directly affecting the smooth muscles of blood vessels, it reduces their response to biogenic vasoconstrictors (adrenaline and norepinephrine). It has a vasodilating effect (especially in relation to cerebral vessels), without having a significant effect on blood pressure. It exhibits moderate antihistamine activity, reduces the excitability of the vestibular apparatus, and lowers the tone of the sympathetic nervous system. Effective in patients with latent cerebral circulatory failure, initial cerebral atherosclerosis and chronic cerebral vascular diseases with post-stroke focal symptoms. In patients with peripheral circulatory disorders, it improves blood supply to organs and tissues (including the myocardium), and enhances post-ischemic vasodilation. Increases the elasticity of red blood cell membranes, their ability to deform, and reduces blood viscosity. Increases muscle resistance to hypoxia.
Indications:
– the period of convalescence after suffering an ischemic and hemorrhagic stroke, traumatic brain injury;
-encephalopathy;
– labyrinthine disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea, vomiting of labyrinthine origin);
-migraine (prevention of attacks);
– Meniere’s disease;
-sea and air sickness (prevention);
– peripheral circulatory disorders (prevention and treatment) – obliterating endarteritis, thromboangiitis obliterans, Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders, trophic and varicose ulcers, pregangrene conditions, paresthesia, night cramps and coldness in the extremities.
Directions for use and dosage:
Inside, after eating. For cerebrovascular accidents – 25-50 mg 3 times a day; for peripheral circulation disorders – 50-75 mg 3 times a day; for labyrinthine disorders – 25 mg 3 times a day; for sea and air sickness, before an upcoming trip for adults – 25 mg, if necessary, repeat the dose after 6 hours.
Children 13 years and older:
Take 1 tablet per day
Children 6-12 years old: take 1/2 tablet per day.
If necessary, the dose is repeated after 6 hours.
Contraindications:
-pregnancy,
– lactation period,
– increased sensitivity to the drug.
With caution: Parkinson’s disease.
Precautionary measures:
At the beginning of treatment, you should refrain from taking ethanol.
Due to the presence of an antihistamine effect, cinnarizine can affect the test result during anti-doping control of athletes (false-positive result), as well as neutralize positive reactions during skin diagnostic tests (treatment should be discontinued 4 days before the test).
With long-term use, it is recommended to conduct a control examination of liver function, kidney function, and peripheral blood patterns.
Women taking cinnarizine are not recommended to breastfeed. Patients with Parkinson’s disease should be prescribed only in cases where the benefits of its use outweigh the possible risk of worsening the condition.
Impact on the ability to drive vehicles and operate machinery:
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Side effects:
From the nervous system: drowsiness, increased fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression.
From the digestive system: dry mouth, pain in the epigastric region, dyspepsia, cholestatic jaundice.
From the skin: increased sweating, lichen planus (extremely rare).
Allergic reactions: skin rash.
Other: decreased blood pressure, increased body weight, development of lupus-like syndrome.
Storage method:
At a temperature not higher than 30 degrees.